Review Article
Autoimmune Hepatitis—Immunologically Triggered Liver Pathogenesis—Diagnostic and Therapeutic Strategies
Table 3
Demographic and descriptive data of AIH patients treated at our institution between 10/2011 and 05/2016.
| | Demographic data | | | Total number 10/2011-05/2016 | | | Age (median) | 50 years | | Male | (42%) | | Female | (58%) | | Cirrhosis | (11%) | | Ascites | (8%) | | Hepatic encephalopathy (grade 1) | (3%) | | MELD, median (range) | 16 (6-23) | | Other autoimmune disease | (55%) | | Simplified AIH score (available for ) | | | Definite AIH () | (27%) | | Probable AIH () | (31%) | | No AIH () | (42%) | | Liver histology (available for ) | | | AIH typical | (29%), interface hepatitis (11%) | | Inconclusive | (25%) | | Not performed | (36%) | | Immunosuppressive therapy | | | Prednisolone (mg), median (range) | 60 mg (50-100 mg) | | Prednisolone therapy duration (days), median (range) | 180 days (60-1080 days) | | Azathioprine (mg), median (range) | 100 mg (50-200 mg) | | Azathioprine start after weeks, median (range) | 3 weeks (1-12 weeks) | | Azathioprine intolerance | (29%) | | Conversion to MMF | (29%) | | Conversion to Everolimus | (5%) | | Outcome | | | Survival | (100%) | | Infection | (3%) | | Liver transplantation | (0%) |
|
|
